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 Key Points 
•  Cardiomyopathies are diseases of the myocardium that can be complicated by heart failure, 
arrhythmias, and sudden death. 
•  Mitochondrial cardiomyopathies are a subgroup of cardiomyopathies produced by defects in the 
energetic metabolism. 
•  Cardiac involvement is reported in 20–25 % of patients with mitochondrial disorders. 
•  Mitochondrial cardiomyopathies can result from mutations in either nuclear or mitochondrial 
encoded genes. 
•  Mitochondrial tRNA Leu , tRNA Ile , and tRNA Val are mutational hotspots for mitochondrial 
cardiomyopathies. 
•  Most patients with mutations in the mitochondrial tRNA Val gene ( MT - TV ) present with a hypertro-
phic cardiomyopathy. 
•  The  MT - TV gene should be included in the molecular diagnosis of patients when there is a high 
suspicion of mitochondrial cardiomyopathy. 
 Abbreviations 
 ARVC  Arrhythmogenic right ventricular cardiomyopathy 
 CM  Cardiomyopathy 
 CPEO  Chronic progressive external ophthalmoplegia 
 DCM  Dilated cardiomyopathy 
 HCM  Hypertrophic cardiomyopathy 
 MCM  Mitochondrial cardiomyopathy 
 Chapter 7 
 Mitochondrial tRNA Valine in Cardiomyopathies 
 M.  Esther  Gallardo ,  Teresa  Galera ,  Rafael  Garesse , and  Belén  Bornstein 
 M. E.  Gallardo,  M.S., Ph.D. (*) •  T.  Galera,  B.S. •  R.  Garesse,  Ph.D. •  B.  Bornstein,  Ph.D. 
 Departamento de Bioquímica, Facultad de Medicina, Instituto de Investigaciones Biomédicas “Alberto Sols” 
UAM-CSIC,  Universidad Autónoma de Madrid ,  Madrid ,  Spain 
 e-mail: egallardo@iib.uam.es 
 Keywords  Mitochondrial disease •  Mitochondrial DNA •  Cardiomyopathy •  Mitochondrial cardio-
myopathy •  MT - TV •  MT - TL1 •  MT - TI 
90
 MD  Mitochondrial disease 
 MELAS  Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
 MiMyCa  Maternally transmitted mitochondrial cardiomyopathy and myopathy 
 MNGIE  Mitochondrial neurogastrointestinal encephalopathy 
 MT-TI  Mitochondrial tRNA isoleucine gene 
 MT-TK  Mitochondrial tRNA lysine gene 
 MT-TV  Mitochondrial tRNA valine gene 
 mtDNA  Mitochondrial DNA 
 OXPHOS  Oxidative phosphorylation 
 RC  Respiratory chain 
 RCM  Restrictive cardiomyopathy 
 tRNA  Transfer ribonucleic acid 
 Introduction 
 Cardiomyopathies (CM) are an important and heterogeneous group of diseases. They are defi ned as 
diseases of the myocardium with cardiac dysfunction that can be complicated by heart failure, arrhyth-
mias, and sudden death [ 1 ]. They are classifi ed into four main different entities: hypertrophic, dilated, 
restrictive, and arrhythmogenic right ventricular CM/ dysplasia (Fig.  7.1 ). Hypertrophic cardiomy-
opathy (HCM) is a clinically heterogeneous but quite common autosomal dominant genetic heart 
disease that probably is the most frequently occurring CM (estimated prevalence of about 1 of 500 
[ 2 – 4 ]). HCM is defi ned by an unexplained left ventricular hypertrophy usually asymmetrical and that 
involves the interventricular septum. The clinical pattern is very heterogeneous. In fact, there are a lot 
of patients without symptoms during their whole life. In some cases HCM may lead to syncope or 
dysnea, sudden death, or congestive heart failure [ 1 ]. Dilated cardiomyopathy (DCM) is the most 
prevalent cause of congestive heart failure in young patients and besides an important cause of cardiac 
transplantation. It has an estimated prevalence of 36 of 100,000 in the US [ 5 ]. Dilated forms of CM 
are characterized by ventricular chamber enlargement and systolic dysfunction, thin wall thickness, 
and depressed left ventricular systolic function [ 6 ]. Restrictive cardiomyopathy (RCM) is a rare form 
of heart muscle disease and a cause of heart failure that is characterized by a pattern of ventricular 
fi lling in which increased stiffness of the myocardium causes ventricular pressure to rise with only 
small increases of volume [ 7 ]. Unlike HCM, DCM, and RCM, arrhythmogenic right ventricular car-
diomyopathy (ARVC) is an uncommon form of inheritable heart muscle disease (estimated in 1:5,000) 
[ 4 ]. ARVC is defi ned histologically by the existence of progressive replacement of right ventricular 
myocardium with adipose and fi brous tissue often confi ned to a triangle of dysplasia comprising the 
right ventricular infl ow, outfl ow, and apex [ 7 ].
 Until now, more than 40 inborn errors in metabolism are reported to cause myocardial abnormali-
ties. They can present with cardiac disease at any moment during life but frequently symptoms and 
signs of multiorgan system dysfunction appear in infancy or early childhood. Most genetic metabolic 
CM are inherited as autosomal recessive traits but some of them are X-linked. Another important 
group of diseases, called mitochondrial cardiomyopathies (MCM), a subgroup of CM produced by 
defects in the energetic metabolism, can result from mutations in either nuclear or mitochondrial 
encoded genes, showing the complexity of the inheritance patterns (e.g., maternal, autosomal reces-
sive) [ 8 ]. This chapter will focus on MCM caused by mutations in the mitochondrial DNA (mtDNA) 
with an emphasis on the mitochondrial tRNA mutations and most specifi cally on mutations identifi ed 
in the mitochondrial tRNA Valine gene ( MT - TV ). 
M.E. Gallardo et al.
91
 Mitochondrial Genetics and Cardiac Disease 
 Disorders of energy production are quite common among inborn errors of metabolism. Mitochondrial 
disorders (MD) are multisystemic diseases that may arise at any age, as a result of dysfunction of the 
respiratory chain (RC). Clinically, they usually involve multiple tissues although the most frequently 
and severely affected organs are those that place high demands on aerobic metabolism, such as brain, 
skeletal muscle, sensory organs, kidney, and cardiac muscle. Myocardium is one of the most energy- 
demanding tissues in the body because of continuous contractility needed for pumping the blood to 
the tissues. This energy is mostly supplied by the mitochondrion, the cellular organelle implicated in 
the generation of energy through the oxidative phosphorylation (OXPHOS). For that reason, it is not 
surprising that mitochondrial diseases can result in either HCM or DCM. CM usually does not appear 
as an isolated feature and it is usually a part of a multisystem involvement. As it has been mentioned 
above MCM can result from inherited or sporadic mutations in mitochondrial (mtDNA) or nuclear 
DNA. Recent studies have reported a minimum birth prevalence of approximately 1 of 8,000 for mito-
chondrial disorders caused by mutations in nuclear or mitochondrial genes although mtDNA muta-
tions are more frequent [ 9 ,  10 ]. The human mtDNA is a 16,569 bp double-stranded circular molecule 
that encodes for 37 genes, 24 of which are involved in the translation mechanism (2 rRNAs and 22 
tRNAs) (Fig.  7.2 ). The 13 remaining genes are responsible for the synthesis of respiratory chain sub-
units. Functional tRNAs are needed for the translation of these 13 proteins as it is shown by the fact 
that mutations in mitochondrial tRNA genes are normally associated with combined defects in the 
respiratory chain complexes [ 11 – 14 ]. However, there are also patients with a mutation in a mitochon-
drial tRNA gene that causes an isolated defi ciency of a complex of the RC [ 14 ,  15 ]. Among the 900 
genes that participate in the correct functioning of mitochondria only a few are located in the mtDNA, 
whereas the rest are encoded in the nucleus. That is the reason why about 50 % of adults and 80–90 % 
of children suspected to have a mitochondrial disease on the basis of biochemical and/or morphologi-
cal data remain genetically undiagnosed [ 16 ].
 Fig. 7.1  Types of 
cardiomyopathies. The fi gure 
shows schematically different 
types of cardiomyopathies. 
 HCM Hypertrophic 
cardiomyopathy,  DCM 
Dilated cardiomyopathy, 
 RCM Restrictive 
cardiomyopathy,  LV Left 
ventricle (unpublished) 
 
7 Mitochondrial tRNA Valine in Cardiomyopathies
92
 MtDNA mutations obey to different genetic rules than those applied to Mendelian diseases. First 
of all, mtDNA is maternally inherited. Second, there are multiple copies of mtDNA in each cell. 
Homoplasmy is the situation in which all mtDNA copies are identical and on the contrary hetero-
plasmy is described when two or more sequence variants exist in a cell or individual. In fact, when 
the ratio of mutant to normal mtDNA exceeds a critical threshold, then the respiratory chain func-
tion will be impaired and the disease appears. The threshold at which symptoms manifest depends 
on the tissue involved. Although the presence of heteroplasmy has been a common pathogenic 
criterion for mitochondrial mutations [ 13 ], homoplasmic mutations are being increasingly recog-
nized as causes of MD [ 13 ,  17 ]. Another aspect of the mitochondrial genetics is the mitotic segrega-
tion of the multiple copies of mtDNA that explains why the level of mutant mtDNA can change 
during life. 
 According to the limited number of reported clinical studies, cardiac involvement is published in 
20–25 % of patients with mitochondrial disorders [ 18 – 20 ]. Cardiac manifestations include CM that 
variably affects the clinical outcome of patients. The course may be stable for many years but rapid 
deterioration may occur [ 8 ]. In spite of the improvement of our knowledge of the molecular mecha-
nisms of these diseases the molecular diagnosis is beginning to have serious implications in the rou-
tine management of this type of patients. 
 Fig. 7.2  Map of the human mitochondrial DNA. The human mtDNA is a circular double-stranded molecule with 
16,559 base pairs of length. It encodes for 13 subunits of the oxidative phosphorylation system: The mitochondrially 
encoded NADH dehydrogenase subunits 1, 2, 3, 4, 4 L, 5, 6 (MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, 
MT-ND5, MT-ND6), the mitochondrially encoded cytochrome c oxidase I, II, and III, (MT-CO1, MT-CO2, MT-CO3), 
the mitochondrially encoded cytochrome b (MT-CYB), the mitochondrially encoded ATP synthase 6 and 8 (MT-ATP6, 
MT-ATP8), 2 rRNAs: rRNA12S, and rRNA16S (MT-RNR1, MT-RNR2), and 22 tRNAs. The tRNA Val gene (MT-TV) 
located between the rRNA12S and rRNA16S is shown (unpublished) 
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 tRNA Mutational Spectrum Associated with CM 
 Mitochondrial diseases (MDs) are a clinically heterogeneous group of disorders caused by dysfunc-
tional mitochondria, the organelles that generate energy for the cell. These diseases can present at any 
age, and their clinical symptoms refl ect a primary defect in tissues with high oxidative demand. Usually, 
changes in blood parameters such as lactate, pyruvate, carnitine, amino acids, and urine organic acids 
are described in these disorders as well as defi ciencies in enzymes of the RC. Although these diseases 
can result from mutations in the nuclear genome most of them are caused by mutations in the mtDNA. In 
spite of the fact that only 10 % of the mtDNA molecule is composed by tRNA genes most of the 
reported mtDNA mutations associated with MD relies on these genes suggesting that these genes are 
prone to mutation [ 17 ]. This conclusion is also supported by a recent study, in which it is confi rmed that 
mitochondrial tRNA genes are mutational hotspots with a frequency of deleterious mutations (exclud-
ing one of the most frequent mutations, the m.3243 A > G) that was almost six times more than that 
occurring in the protein-coding regions [ 21 ]. Until now mutations in all mitochondrial tRNAs have 
been described associated with several MD (see MITOMAP database:  http://www.mitomap.org/ ). 
However, the mitochondrial tRNA Leu ( MT - TL1 ), tRNA Lys ( MT - TK ), and tRNA Ile ( MT - TI ) appear 
to be more susceptible to mutation [ 22 ]. In fact, there have been described 35 mutations associated with 
MD in the  MT - TL1 , 22 in the  MT - TK , and 20 in the  MT - TI . By contrast, only three mutations in the 
mitochondrial tRNA Asp ( MT - TD ) and two in the mitochondrial tRNA Tyr ( MT - TY ) have been found. 
 The predominance of neurologic and neuromuscular manifestations in MD has generally masked the 
presence of other, but not less important, clinical phenotypes, such as cardiac complications. This may 
be one of the fact that has prevented the diagnosis of mitochondrial cardiomyopathies (MCMs) [ 14 ]. 
Nowadays, mitochondrial defects are being increasingly recognized to play an important role in the 
pathogenesis of hereditary cardiomyopathies [ 8 ]. Indeed, sporadic or inherited mutations in mitochon-
drial DNA (mtDNA), specifi cally in the mtDNA transfer ribonucleic acid (tRNA) genes, or in the nuclear 
genome, have been associated with hypertrophic and dilated cardiomyopathy [ 23 ,  24 ]. In the same way 
cardiac conduction abnormalities have also been associated with different mtDNA rearrangements [ 25 ]. 
 Based on the prevalence data of mtDNA diseases and the frequency of cardiac involvement, at least 
1 in 10–15,000 of the general population will be affected. In 1991, the fi rst mitochondrial DNA 
(mtDNA) point mutation in the  MT - TL1 gene (m.3260A > G) associated with a maternally transmitted 
MCM and myopathy was identifi ed and the acronym MiMyCa was described [ 26 ]. Since then, several 
mutations in the mtDNA, mostly in mitochondrial tRNA genes have been associated with different 
MCM phenotypes (HCM and DCM) [ 25 ]. These diseases are preferentially linked to mutations in the 
 MT - TL1 , and  MT - TI genes [ 8 ,  27 ,  28 ]. The  MT - TL1 gene provides instructions for making a specifi c 
form of tRNA, present only in mitochondria, called tRNA Leu(UUR) and the mitochondrially encoded 
tRNA isoleucine also known as  MT - TI is a tRNA which in humans is encoded by the mitochondrial 
 MT - TI gene. During protein assembly, these molecules attach to the amino acids Leucine and 
Isoleucine (both branched chain amino acids) and insert it into the appropriate locations in the protein. 
In Table  7.1 are shown the mutations in the  MT - TI and  MT - TL1 genes that have been associated with 
CM. A remarkable fact is that if we consider all the mitochondrial tRNAs the ones with more muta-
tions associated to CM are the mitochondrial tRNA Leu , tRNA Ile , tRNA Lys , and tRNA Val (the latter 
described in more detail in the next section).
 Cardiomyopathies Due to Mitochondrial tRNA Val Mutations 
 The mitochondrially encoded tRNA Valine is a transfer RNA encoded by the mitochondrial  MT - TV 
gene.  MT-TV is a 69 nucleotide RNA (located in position 1602–1670 bp of the mtDNA molecule). The 
tRNA Val attaches to a particular branched chain amino acid, Valine, and inserts it into the suitable 
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locations in many different proteins. The tRNA Val molecule is involved in the assembly of proteins 
that carry out OXPHOS. 
 Mitochondrial diseases caused by mutations in the  MT - TV gene are not very frequent. In 1996, the 
fi rst mutation in this gene (m.1642G > A) was described in a patient with a MELAS phenotype (mito-
chondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) [ 29 ]. Since then, a total of 
eleven mutations in the  MT - TV gene associated with a wide range of phenotypes, including MELAS, 
Leigh syndrome, CPEO (Chronic progressive external ophthalmoplegia), MNGIE (mitochondrial 
neurogastrointestinal encephalopathy), or HCM have been identifi ed (Table  7.2 ).
 Five of these mutations (m.1606G > A, m.1607 T > C, m.1630A > G, m.1642G > A, m.1644G > T) 
were heteroplasmic in all patients studied and three were homoplasmic (m.1624C > T, m.1628C > T, 
m.1643A > G) (Table  7.2 ). The m.1659 T > C can also be considered homoplasmic, because in all 
tissues analysed (blood, muscle, buccal epithelia, and urinary epithelia) the heteroplasmy level was 
higher than 98 % [ 22 ]. The transition (m.1644G > A) was shown both in heteroplasmy (85 %) [ 30 ] 
and homoplasmy [ 14 ]. Interestingly, the patient with the m.1644G > A mutation in homoplasmy has 
a more severe clinical phenotype, including cardiac involvement which was absent in the patient with 
the mutation in heteroplasmy (Table  7.2 ). Finally, the heteroplasmy levels of the m.1658 T > C 
sequence change were not determined in the study, although the electropherogram shows hetero-
plasmy levels near to 100 % [ 31 ]. 
 Only fi ve mutations from the eleven published in the  MT - TV gene have already been associated 
with cardiac conduction abnormalities and HCM within a neurological presentation (m.1624C > T, 
m.1628C > T; m.1644G > A; m.1644G > T and m.1659 T > C) ([ 11 ,  14 ,  22 ] (Table  7.2 ; Fig.  7.3 ). These 
data suggest that although the  MT - TV gene is not a region prone to mutation compared with other 
mitochondrial tRNAs, such as  MT - TL ,  MT - TI , and  MT - TK , a relatively high percentage of mutations 
in this gene (45 %: 5/11) are associated with MCM. In consequence, the  MT - TV gene should also be 
included in the molecular diagnosis of patients when there is a high suspicion of MCM [ 14 ]. 
Interestingly, all patients with  MT - TV mutations associated with MCM presented with a hypertrophic 
subtype (Table  7.2 ).
 Although the nucleotide changes described in the  MT - TV gene associated with HCM were thought 
to be pathogenic following several molecular criteria only two (m.1624C > T; m.1644G > A) were 
probed to be pathogenic in functional assays (Table  7.2 ). The pathogenicity of the m.1624C > T 
nucleotide change was confi rmed by means of transmitochondrial cybrids [ 32 ,  33 ], and a selective 
reduction of the steady-state mt-tRNA Val level in muscle from the patient harbouring the m.1644G > A 
transition, supports both the cardiac and the neurological involvement of this mutation [ 14 ]. Due to 
the lack of sample it could not be confi rmed whether this mutation may lead to a conformational 
change or impaired aminoacylation capacity of the mt-tRNA Val [ 14 ]. 
 A particular feature of mutations in mitochondrial tRNAs and in mtDNA in general is that a clear 
correlation between genotype-phenotype does not exit. That means that the same mutations are asso-
ciated to different clinical phenotypes (clinical heterogeneity) and the same disease is associated with 
different mutations (genetic heterogeneity). As examples of the clinical heterogeneity, the homoplas-
mic mutation m.1624C > T in the  MT - TV gene can generate from mild to severe phenotypes between 
the family members [ 13 ] or even mutations at the same nucleotide of the  MT - TV gene (m.1644G > A 
and m.1644G > T) result in different phenotypes (Hypertrophic cardiomyopathy plus MELAS or 
Leigh Syndrome respectively) [ 11 ,  30 ,  34 ]. 
 There are several explanations for the absence of genotype-phenotype correlation. Among them are 
the nuclear background, the heteroplasmy levels and its tissue distribution, the mtDNA haplotype, or 
the total mtDNA copy number [ 35 ]. The importance of the nuclear background in the clinical pheno-
type is highlighted in a recent study, in which the tRNA Val steady-state level in transmitochondrial 
cybrids carrying the m.1624C > T mutation in homoplasmy (10 % referred to controls) differs signifi -
cantly of the level observed in muscle biopsy with the same mutation in homoplasmy (<1 % referred 
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to controls) [ 32 ]. To date, the most pronounced decrease of the steaty-state mitochondrial tRNA Val in 
cardiac and in skeletal muscles has been observed in the presence of this mutation associated with 
infantile and fatal Leigh syndrome together with severe cardiac failure in one of ten children affected 
[ 13 ]. Regarding the quantity of mutant mtDNA, although there are examples of maternally inherited 
mutations in which the severity of the disease correlates with the number of mutated copies [ 11 ], there 
are also examples in which the level of heteroplasmy do not correlate with the presence or severity of 
the disease. As an example the mutation m.1630A > G (not associated with a cardiac dysfunction; 
Table  7.2 ) has been reported to be in higher levels in a healthy mother (93 % in blood and 98 % in urine) 
than in her affected daughter (75 % in blood, 95 % in urine, and 60 % in fi broblast) [ 33 ]. 
 Pathogenic mutations in mitochondrial tRNAs can alter the secondary structure or change one 
highly conserved base to another base, abolish the tertiary structure, and lead to dysfunction. Mutations 
in them affect biogenesis and function of mitochondrial tRNAs by several mechanisms, including 
transcription, maturation, posttranscriptional modifi cation, structure, stability, aminoacylation, capa-
bility of binding to elongation factor thermo-unstable (EF-Tu), and Codon Reading [ 33 ,  36 ]. 
 The pathogenic effect mediated by a structural change is in accordance with the work performed 
by [ 37 ]. In this study they demonstrated that mutations in different mitochondrial tRNAs but at the 
same position of the cloverleaf originate the same clinical phenotype. For example, mutations located 
at position 5 of the cloverleaf (m.1606G > A and m.7512 T > C in the  MT - TV and  MT - TS genes respec-
tively) produce neurological symptoms, myopathy, and hearing loss, and mutations at the position 72 
(m.3303C > T and m.8363G > A of the  MT - TL1 and  MT - TK respectively) are associated with CM. On 
the contrary, mutations at the same position of the same gene have been reported to be associated with 
different phenotypes. For example, m.1644G > A and m.1644G > T mutations in the tRNA Val cause 
different clinical phenotypes, MELAS, or HCM with neurogastrointestinal manifestations in the fi rst 
case [ 14 ,  30 ] and adult Leigh syndrome in the second case [ 11 ,  34 ]. 
 Fig. 7.3  Schematic 
representation of the 
mitochondrial tRNA Val 
structure. A total of 11 
mutations in the  MT - TV gene 
associated with a wide range 
of phenotypes, including 
MELAS, Leigh syndrome, 
CPEO, MNGIE, or HCM 
have been represented. 
Mutations specifi cally 
associated with CM are 
highlighted with an  asterisk. 
HCM Hypertrophic 
cardiomyopathy,  MELAS 
Mitochondrial 
encephalomyopathy, lactic 
acidosis, and stroke-like 
episodes,  CPEO Chronic 
progressive external 
ophthalmoplegia,  MNGIE 
Mitochondrial 
neurogastrointestinal 
encephalopathy disease 
(unpublished) 
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 Regarding the  MT - TV gene, its location between the 12S and the 16S ribosomal RNAs could 
explain by an indirect way how mutations in this gene could originate a pathogenic phenotype. Both 
rRNAs and the tRNA Val are transcribed as a polycistronic messenger with the posterior cleavage by the 
RNAse P-like endonuclease [ 38 ]. For that reason, it has been hypothesised that mutations in the 
tRNA Val could interrupt the normal cleavage of the polycistronic messenger and, this could be the 
reason of the disease. However, in a study performed by [ 39 ] with the m.1642G > A mutation, no 
abnormality in the splicing data was observed. This data suggest that this mechanism by itself cannot 
explain the observed phenotype. 
 Due to the fact that the  MT - TV gene is being increasingly recognized as cause of MCM, an impor-
tant effort in improving the knowledge about the molecular mechanisms that could explain the reason 
why the disease appears must be carried out. 
 Conclusions 
 Mitochondrial dysfunction frequently affects the heart and can produce both hypertrophic and dilated 
CM. CM are among the most severe presentations of OXPHOS with a relatively high morbidity and 
mortality. Due to the fact that genetics and biochemical aspects of the mitochondrion and mitochon-
drial disorders are beginning to be better understood, the pathophysiologic features of the mitochon-
drial heart disease are also becoming to be understood. 
 In spite of the improvement of our comprehension of the molecular mechanisms of these diseases 
the molecular diagnosis is beginning to have serious repercussions in the routine management of these 
patients. Indeed, an appropriate diagnosis of a mitochondrial cardiomyopathy could have not only 
important clinical implications but also could open new possibilities towards the development of 
potential future therapeutic strategies for these diseases which at this moment only have palliative 
therapeutic approaches. 
 The discovery that the  MT - TV gene is another mutational hotspot for MCM will allow physicians 
to offer better genetic counselling. However more exhaustive sequencing strategies that involve the 
use of next generation sequencing will be needed to identify new molecular genetic causes in patients 
with MCM. 
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